Changzhou Jiayuan Chemical participated in the 23rd World Pharmaceutical Raw Materials China Exhibition, deeply grasping the cutting-edge trends of the industry
June 24, 2025 , the three-day 23rd World Pharmaceutical Ingredients China Exhibition (CPHI China 2025) opened at the Shanghai New International Expo Center . As a backbone enterprise in the field of domestic pharmaceutical intermediates and APIs, Changzhou Jiayuan Chemical Co., Ltd. (hereinafter referred to as "Jiayuan Chemical") exhibited its core products such as 1 , 4-butynediol , hexafluoroisopropanol , zinc sulfate heptahydrate and other fluorine chemical products. Through exchanges with global industry chain partners and in-depth participation in the forum at the same time, it systematically mastered the current technological innovation, policy orientation and market dynamics of the pharmaceutical industry, injecting new momentum into the strategic upgrade of the enterprise.
1. The process of global pharmaceutical regulatory coordination is accelerating, and compliance has become a core issue for “going global”
Jiayuan Chemical learned from the International Pharmaceutical Policy Q&A Session and the API Internationalization Salon that the quality requirements for APIs in Europe, America and emerging markets continue to upgrade:
Strengthening GMP compliance in Europe and the United States : FDA and EMA are pushing API factories to adopt "dynamic Good Manufacturing Practice" (dGMP), requiring real-time traceability of data throughout the entire production process.
Simplified access to emerging markets : The Association of Southeast Asian Nations (ASEAN) plans to unify the format of drug registration documents among 10 countries by 2026 to reduce regional trade barriers.
Support for China's innovative drugs to go global : The International Registration Service Center of the National Medical Products Administration participated in the exhibition for the first time and announced that it would provide special training on ICH guidelines (Q3D metal impurity control, etc.) for small and medium-sized enterprises.
2. Biopharmaceuticals and green synthesis technologies lead the innovation wave
Explosive growth of biopharmaceuticals :
The demand for cell and gene therapy (CGT) raw materials increases by 35% annually, and nucleic acid intermediates (such as mCap modified nucleosides) become scarce resources.
In the demonstration of toxin-linker technology for antibody-drug conjugates (ADCs), the "cleavable linker" developed by a Korean company significantly improved drug targeting.
Green synthesis technology implementation :
The first public demonstration of an enzyme-catalyzed continuous flow reaction device, which can reduce the energy consumption of API synthesis by 40%;
The new EU regulations require that the carbon footprint of API production be reduced by 50% by 2030, and catalytic hydrogenation has become a technological hotspot to replace heavy metal reduction.